High-profile gene editing startup Tome Biosciences is set to terminate nearly all of its staff starting November 1, according to a legal filing. The company has reportedly struggled to raise funds or find a partner, leading to plans to wind down operations and seek a buyer by the same date. Despite stating that it is only operating at reduced capacity and maintaining core expertise, the company’s Massachusetts WARN notice indicates major layoffs. Tome Biosciences has been exploring strategic options in the face of financial challenges, with the fate of the startup hanging in the balance.
Source link
Tome Biosciences to lay off nearly entire staff
